Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.morepen.com | |
Market Cap | 1,312.68 Cr. | |
Enterprise Value(EV) | 1,294.84 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.84 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 30.70 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.41 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 14.23 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 1.80 | Calculated using Price: 25.68 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 51.12 Cr. | 511,168,708 Shares |
FaceValue | 2 | |
Company Profile | ||
Established in the year 1984, Morepen Laboratories is a fast growing Pharmaceutical company listed in all major stock exchanges in India including Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) since 1993 with an investors base of 62,400 shareholders. |
1 Day |
|
-0.47% |
1 Week |
|
+5.12% |
1 Month |
|
+1.10% |
3 Month |
|
-32.06% |
6 Month |
|
+7.45% |
1 Year |
|
-29.84% |
2 Year |
|
-20.12% |
5 Year |
|
-16.76% |
10 Year |
|
+923.11% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | -1.54 | 1.24 | 7.35 | 12.54 | 14.10 | 12.04 | 12.50 | 29.20 | 21.79 | |
Return on Capital Employed (%) | 1.80 | 2.90 | 6.29 | 10.18 | 14.05 | 10.01 | 12.05 | 27.13 | 24.86 | |
Return on Assets (%) | -0.55 | 0.44 | 2.53 | 4.45 | 5.30 | 4.80 | 5.25 | 12.76 | 10.55 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 297 | 287 | 300 | 196 | 226 | 253 | 284 | 425 | 579 | 737 | |
Non Curr. Liab. | 85 | 74 | 57 | 18 | 20 | 23 | 28 | 30 | 36 | 35 | |
Curr. Liab. | 108 | 128 | 167 | 325 | 340 | 339 | 351 | 404 | 456 | 280 | |
Minority Int. | 0 | 0 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | |
Equity & Liab. | 490 | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,052 | |
Non Curr. Assets | 393 | 374 | 367 | 346 | 342 | 316 | 291 | 331 | 336 | 351 | |
Curr. Assets | 96 | 115 | 157 | 192 | 243 | 299 | 372 | 527 | 734 | 701 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 490 | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,052 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 367 | 401 | 485 | 595 | 607 | 769 | 853 | 1,188 | 1,547 | 1,422 | |
Other Income | 1 | 1 | 1 | 4 | 4 | 4 | 9 | 12 | 20 | 6 | |
Total Income | 368 | 402 | 486 | 599 | 610 | 772 | 863 | 1,200 | 1,567 | 1,428 | |
Total Expenditure | -318 | -352 | -424 | -534 | -542 | -701 | -785 | -1,070 | -1,410 | -1,339 | |
PBIDT | 50 | 50 | 63 | 65 | 68 | 71 | 78 | 131 | 157 | 89 | |
Interest | -10 | -9 | -11 | -8 | -4 | -2 | -2 | -2 | -2 | -2 | |
Depreciation | -46 | -39 | -35 | -34 | -34 | -40 | -37 | -30 | -28 | -28 | |
Taxation | 0 | 0 | 0 | 0 | -6 | -1 | -25 | -16 | |||
Exceptional Items | 3 | -4 | |||||||||
PAT | -3 | 2 | 13 | 24 | 30 | 29 | 34 | 97 | 102 | 43 | |
Minority Interest | 0 | 0 | 0 | ||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | -3 | 2 | 13 | 24 | 30 | 29 | 34 | 97 | 102 | 43 | |
Adjusted EPS | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 1 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 34 | 34 | 51 | 50 | 41 | 63 | 17 | 11 | 51 | -58 | |
Cash Fr. Inv. | -3 | -1 | -32 | -27 | -14 | -27 | -13 | -12 | -70 | -32 | |
Cash Fr. Finan. | -30 | -29 | -19 | -27 | -24 | -38 | 0 | 5 | 47 | 64 | |
Net Change | 1 | 4 | 0 | -4 | 3 | -1 | 4 | 4 | 28 | -26 | |
Cash & Cash Eqvt | 6 | 9 | 9 | 4 | 7 | 6 | 10 | 14 | 41 | 16 |
Fri, 31 Mar 2023
Closure of Trading Window Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 as amended and in accordance with the Code of Conduct to Regulate Monitor and Report of Trading by Insiders for trading in Companys Shares/ Securities the Trading Window will remain closed with effect from April 01 2023 for the purpose of consideration and approval of audited financial results for the quarter and financial year ended March 31 2023.During the aforesaid closed trading window period the Designated Persons shall not trade in Companys shares/ securities.The Trading Window shall remain closed till 48 hours after the announcement of the said financial results when the information becomes generally available. |
Tue, 28 Mar 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended please find attached herewith letters dated 28th March 2023 received from Registrar and Share Transfer Agent of the company (viz. MAS Services Limited) regarding loss of share certificates of the company. In terms of SEBI Circular No. SEBI / HO / MIRSD / MIRSD_RTAMB / P / CIR /2022/8 dated 25th January 2022 the company shall issue Letter of Confirmation to the concerned shareholder after compliance of requisite formalities. |
Sat, 25 Mar 2023
Successful Completion Of USFDA Inspection Of API Facility At Baddi (H.P.) This is to inform you that the United States Food and Drug Administration (USFDA) conducted an inspection of the API manufacturing facility at Baddi Himachal Pradesh of the company.The facility has been cleared by USFDA on 24th March 2023 without any adverse observation (NIL 483). |
Fri, 31 Mar 2023 |
|
|
|
|
Wed, 29 Mar 2023 |
|